The Hevolution Foundation and other investors provided additional funding in a Series A round totaling USD 30.7 m.

Vandria discovers and develops novel small molecules that induce mitophagy to treat in particular age-related and chronic diseases.

Hevolution Foundation is a global non-profit organization that provides grants and early-stage investments to incentivize independent research and entrepreneurship in the emerging field of health span science.

The Homburger team advising Hevolution Foundation included Andreas Müller and Marc Abplanalp (both Corporate / M&A), Luca Dal Molin and Joel Fink (both IP / IT) and Jeremy Reichlin (Employment and Executive Compensation).